<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7585">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00911144</url>
  </required_header>
  <id_info>
    <org_study_id>112933</org_study_id>
    <nct_id>NCT00911144</nct_id>
  </id_info>
  <brief_title>Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine</brief_title>
  <official_title>Booster Vaccination With Pneumococcal Vaccine GSK1024850A or Prevenar™ Co-administered With Hiberix™ in Children Primed With the Same Vaccines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Korea: Korea Food &amp; Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of a
      booster (fourth) dose of pneumococcal vaccine GSK1024850A when co-administered with Hiberix
      at 12-18 months of age, in children primed with the same vaccines in primary study
      NCT00680914.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Subjects Reporting Grade 3 Adverse Events</measure>
    <time_frame>Within 31 days (Day 0 - Day 30) after booster vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Grade 3 adverse events are severe symptoms that prevent normal, everyday activities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Symptoms</measure>
    <time_frame>Within 4 days (Days 0 to 3) after booster vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited local symptoms assessed include pain, redness and swelling at the injection site. Solicited general symptoms assessed include drowsiness, fever (equal to or above 37.5 degrees Celsius), irritability and loss of appetite.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events</measure>
    <time_frame>Within 31 days (Days 0 to 30) after booster vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study. Also any &quot;solicited&quot; symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events</measure>
    <time_frame>After booster vaccination up to study end (Month 0 to Month 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serious adverse events are medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Antibodies Against Vaccine Pneumococcal Serotypes</measure>
    <time_frame>One month after booster vaccination (Month 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentrations of antibodies are measured by 22F-inhibition enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations expressed as microgram per milliliter.
Vaccine pneumococcal serotypes included serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes</measure>
    <time_frame>One month after booster vaccination (Month 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Streptococcus pneumoniae opsonophagocytic activity was measured by a killing-assay using a HL 60 cell line. The results are presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions.
Vaccine pneumococcal serotypes included serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A</measure>
    <time_frame>One month after booster vaccination (Month 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentrations of antibodies are measured by 22F-inhibition ELISA and are presented as geometric mean concentrations expressed as microgram per milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A</measure>
    <time_frame>One month after booster vaccination (Month 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Streptococcus pneumoniae opsonophagocytic activity was measured by a killing-assay using a HL 60 cell line. The results are presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Antibodies Against Protein D (PD)</measure>
    <time_frame>One month after booster vaccination (Month 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentrations of antibodies are presented as geometric mean concentrations expressed as Enzyme-Linked Immuno-Sorbent Assay (ELISA) units per milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Antibodies Against Polyribosyl-ribitol-phosphate (PRP)</measure>
    <time_frame>One month after booster vaccination (Month 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentrations of antibodies are presented as geometric mean concentrations expressed as microgram per milliliter.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">450</enrollment>
  <condition>Streptococcus Pneumoniae</condition>
  <condition>Pneumococcal Diseases</condition>
  <arm_group>
    <arm_group_label>Synflorix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevenar Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A)</intervention_name>
    <description>Intramuscular injection, administered as a single dose</description>
    <arm_group_label>Synflorix Group</arm_group_label>
    <other_name>Pneumococcal vaccine GSK1024850A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Wyeth-Lederle's Prevenar™</intervention_name>
    <description>Intramuscular injection, administered as a single dose</description>
    <arm_group_label>Prevenar Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' Hiberix™</intervention_name>
    <description>Intramuscular injection, administered as a single dose</description>
    <arm_group_label>Prevenar Group</arm_group_label>
    <arm_group_label>Synflorix Group</arm_group_label>
    <other_name>Hib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female between, and including, 12-18 months of age at the time of booster
             vaccination.

          -  Subjects for whom the investigator believes that their parent(s)/ guardian(s) can and
             will comply with the requirements of the protocol.

          -  Subjects who received three doses of pneumococcal conjugate vaccine in study
             NCT00680914.

          -  Written informed consent obtained from the parent(s)/guardian(s) of the child/ward.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) within 30 days
             preceding the vaccination, or planned use during the study period.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product (pharmaceutical product or device).

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to vaccination.

          -  Administration of immunoglobulins and/or any blood products within three months
             preceding the vaccination or planned administration during the study period.

          -  Administration of any pneumococcal and/or Hib vaccine since the end of study
             NCT00680914.

          -  Planned administration/administration of a vaccine not allowed by the study protocol
             during the period starting 1 month (30 days) before the administration of the booster
             dose of the study vaccines (Visit 1) and up to the follow-up visit (Visit 2) with the
             exception of vaccines included in the Korean routine immunization which can be given
             at least one week before the administration of the study vaccines or after study end.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  History of reactions or allergic disease likely to be exacerbated by any component of
             the study vaccines.

          -  Known hypersensitivity to any component of the study vaccines including anaphylactic
             reactions following the administration of the study vaccines.

          -  Major congenital defects or serious chronic illness.

          -  History of any neurologic disorders or seizures.

          -  Tympanic or axillary/ oral temperature &gt;= 37.5°C or rectal temperature &gt;= 38.0°C. A
             temperature greater than or equal to these cut-offs warrants deferral of the
             vaccination pending recovery of the subject.

          -  Acute disease at the time of enrolment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ansan</city>
        <zip>425-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucheon-Si, GyeongGi-do,</city>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Daejeon</city>
        <zip>301-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>411-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>GyeongSangNam-do</city>
        <zip>641-560</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iksan</city>
        <zip>570-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jeju City</city>
        <zip>690-121</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jeonju Jeonbuk</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>150-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Suwon City, Gyeonggi-do</city>
        <zip>442-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wonju-si Kangwon-do</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>November 10, 2011</lastchanged_date>
  <firstreceived_date>May 28, 2009</firstreceived_date>
  <firstreceived_results_date>January 6, 2011</firstreceived_results_date>
  <responsible_party>
    <name_title>Cheri Hudson; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Pneumococcal vaccine</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Pneumococcal disease</keyword>
  <keyword>Booster vaccination</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two subjects enrolled in the protocol received commercial Prevenar and Hiberix vaccines instead of the clinical vaccines planned to be injected and are as such not included in the number of started subjects below.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Synflorix Group</title>
          <description>Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
        </group>
        <group group_id="P2">
          <title>Prevenar Group</title>
          <description>Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="335"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="319"/>
                <participants group_id="P2" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Synflorix Group</title>
          <description>Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
        </group>
        <group group_id="B2">
          <title>Prevenar Group</title>
          <description>Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="335"/>
                <measurement group_id="B2" value="113"/>
                <measurement group_id="B3" value="448"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="13.6" spread="1.07"/>
                <measurement group_id="B2" value="13.7" spread="1.00"/>
                <measurement group_id="B3" value="13.6" spread="1.05"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="168"/>
                <measurement group_id="B2" value="59"/>
                <measurement group_id="B3" value="227"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="167"/>
                <measurement group_id="B2" value="54"/>
                <measurement group_id="B3" value="221"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Grade 3 Adverse Events</title>
        <description>Grade 3 adverse events are severe symptoms that prevent normal, everyday activities.</description>
        <time_frame>Within 31 days (Day 0 - Day 30) after booster vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total vaccinated cohort on the subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="332"/>
                  <measurement group_id="O2" value="113"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Grade 3 Adverse Events</title>
            <description>Grade 3 adverse events are severe symptoms that prevent normal, everyday activities.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling at the injection site. Solicited general symptoms assessed include drowsiness, fever (equal to or above 37.5 degrees Celsius), irritability and loss of appetite.</description>
        <time_frame>Within 4 days (Days 0 to 3) after booster vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total vaccinated cohort on the subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="332"/>
                  <measurement group_id="O2" value="113"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Solicited Symptoms</title>
            <description>Solicited local symptoms assessed include pain, redness and swelling at the injection site. Solicited general symptoms assessed include drowsiness, fever (equal to or above 37.5 degrees Celsius), irritability and loss of appetite.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="120"/>
                  <measurement group_id="O2" value="39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="142"/>
                  <measurement group_id="O2" value="55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="97"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Drowsiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Irritability</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="141"/>
                  <measurement group_id="O2" value="42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Loss of appetite</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events</title>
        <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study. Also any “solicited” symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.</description>
        <time_frame>Within 31 days (Days 0 to 30) after booster vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="335"/>
                  <measurement group_id="O2" value="113"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Unsolicited Adverse Events</title>
            <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study. Also any “solicited” symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="118"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events</title>
        <description>Serious adverse events are medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>After booster vaccination up to study end (Month 0 to Month 1)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="335"/>
                  <measurement group_id="O2" value="113"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Serious Adverse Events</title>
            <description>Serious adverse events are medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Antibodies Against Vaccine Pneumococcal Serotypes</title>
        <description>Concentrations of antibodies are measured by 22F-inhibition enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations expressed as microgram per milliliter.
Vaccine pneumococcal serotypes included serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
        <time_frame>One month after booster vaccination (Month 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data were available for antibodies against at least one study vaccine antigen after booster vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="317"/>
                  <measurement group_id="O2" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Concentration of Antibodies Against Vaccine Pneumococcal Serotypes</title>
            <description>Concentrations of antibodies are measured by 22F-inhibition enzyme-linked immunosorbent assay (ELISA) and are presented as geometric mean concentrations expressed as microgram per milliliter.
Vaccine pneumococcal serotypes included serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
            <units>microgram per milliliter</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-1 (n= 317, 100)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.03" lower_limit="3.66" upper_limit="4.43"/>
                  <measurement group_id="O2" value="0.06" lower_limit="0.05" upper_limit="0.07"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-4 (n= 317, 102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.77" lower_limit="5.25" upper_limit="6.34"/>
                  <measurement group_id="O2" value="12.19" lower_limit="10.11" upper_limit="14.69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-5 (n= 317, 102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.51" lower_limit="5.08" upper_limit="5.98"/>
                  <measurement group_id="O2" value="0.19" lower_limit="0.16" upper_limit="0.23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-6B (n= 317, 102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.78" lower_limit="2.48" upper_limit="3.12"/>
                  <measurement group_id="O2" value="7.09" lower_limit="5.82" upper_limit="8.63"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-7F (n= 317, 102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.39" lower_limit="4.97" upper_limit="5.85"/>
                  <measurement group_id="O2" value="0.06" lower_limit="0.04" upper_limit="0.07"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-9V (n= 317, 102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.99" lower_limit="4.55" upper_limit="5.46"/>
                  <measurement group_id="O2" value="12.72" lower_limit="10.86" upper_limit="14.88"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-14 (n= 316, 102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.73" lower_limit="7.09" upper_limit="8.43"/>
                  <measurement group_id="O2" value="22.22" lower_limit="18.96" upper_limit="26.03"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-18C (n= 317, 102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.14" lower_limit="11.90" upper_limit="14.52"/>
                  <measurement group_id="O2" value="14.53" lower_limit="12.10" upper_limit="17.44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-19F (n= 317, 101)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.89" lower_limit="14.87" upper_limit="19.20"/>
                  <measurement group_id="O2" value="4.82" lower_limit="3.97" upper_limit="5.85"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-23F (n= 317, 102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.75" lower_limit="3.37" upper_limit="4.16"/>
                  <measurement group_id="O2" value="14.81" lower_limit="11.61" upper_limit="18.89"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes</title>
        <description>Streptococcus pneumoniae opsonophagocytic activity was measured by a killing-assay using a HL 60 cell line. The results are presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions.
Vaccine pneumococcal serotypes included serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
        <time_frame>One month after booster vaccination (Month 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data were available for antibodies against at least one study vaccine antigen after booster vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="151"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes</title>
            <description>Streptococcus pneumoniae opsonophagocytic activity was measured by a killing-assay using a HL 60 cell line. The results are presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions.
Vaccine pneumococcal serotypes included serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.</description>
            <units>titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Opsono-1 (n= 148, 47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="363.7" lower_limit="275.3" upper_limit="480.5"/>
                  <measurement group_id="O2" value="4.7" lower_limit="3.9" upper_limit="5.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-4 (n= 149, 45)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1058.0" lower_limit="893.9" upper_limit="1252.3"/>
                  <measurement group_id="O2" value="3717.0" lower_limit="2759.3" upper_limit="5007.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-5 (n= 150, 46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="233.9" lower_limit="189.8" upper_limit="288.3"/>
                  <measurement group_id="O2" value="4.0" lower_limit="4.0" upper_limit="4.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-6B (n= 150, 46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="546.5" lower_limit="415.9" upper_limit="718.0"/>
                  <measurement group_id="O2" value="3826.8" lower_limit="2518.0" upper_limit="5815.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-7F (n= 145, 46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5467.5" lower_limit="4698.1" upper_limit="6363.0"/>
                  <measurement group_id="O2" value="1038.2" lower_limit="609.9" upper_limit="1767.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-9V (n= 151, 44)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1707.5" lower_limit="1497.6" upper_limit="1946.8"/>
                  <measurement group_id="O2" value="5204.0" lower_limit="3842.8" upper_limit="7047.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-14 (n= 150, 46)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1814.6" lower_limit="1577.4" upper_limit="2087.5"/>
                  <measurement group_id="O2" value="3958.4" lower_limit="2888.1" upper_limit="5425.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-18C (n= 147, 45)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="607.9" lower_limit="498.2" upper_limit="741.6"/>
                  <measurement group_id="O2" value="1723.3" lower_limit="1196.4" upper_limit="2482.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-19F (n= 149, 44)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1284.5" lower_limit="1027.2" upper_limit="1606.3"/>
                  <measurement group_id="O2" value="277.3" lower_limit="171.6" upper_limit="448.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-23F (n= 149, 44)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2702.9" lower_limit="2234.9" upper_limit="3268.9"/>
                  <measurement group_id="O2" value="29918.6" lower_limit="17115.7" upper_limit="52298.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A</title>
        <description>Concentrations of antibodies are measured by 22F-inhibition ELISA and are presented as geometric mean concentrations expressed as microgram per milliliter.</description>
        <time_frame>One month after booster vaccination (Month 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data were available for antibodies against at least one study vaccine antigen after booster vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="317"/>
                  <measurement group_id="O2" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Concentration of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A</title>
            <description>Concentrations of antibodies are measured by 22F-inhibition ELISA and are presented as geometric mean concentrations expressed as microgram per milliliter.</description>
            <units>microgram per milliliter</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-6A</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.99" lower_limit="0.84" upper_limit="1.17"/>
                  <measurement group_id="O2" value="2.51" lower_limit="1.79" upper_limit="3.51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-19A</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.54" lower_limit="1.27" upper_limit="1.87"/>
                  <measurement group_id="O2" value="0.32" lower_limit="0.24" upper_limit="0.43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A</title>
        <description>Streptococcus pneumoniae opsonophagocytic activity was measured by a killing-assay using a HL 60 cell line. The results are presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions.</description>
        <time_frame>One month after booster vaccination (Month 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data were available for antibodies against at least one study vaccine antigen after booster vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="146"/>
                  <measurement group_id="O2" value="44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A</title>
            <description>Streptococcus pneumoniae opsonophagocytic activity was measured by a killing-assay using a HL 60 cell line. The results are presented as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions.</description>
            <units>titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Opsono-6A (n= 137, 44)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="196.1" lower_limit="134.6" upper_limit="285.9"/>
                  <measurement group_id="O2" value="1415.7" lower_limit="891.2" upper_limit="2248.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Opsono-19A (n= 146, 44)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64.9" lower_limit="44.6" upper_limit="94.5"/>
                  <measurement group_id="O2" value="15.5" lower_limit="8.1" upper_limit="29.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Antibodies Against Protein D (PD)</title>
        <description>Concentrations of antibodies are presented as geometric mean concentrations expressed as Enzyme-Linked Immuno-Sorbent Assay (ELISA) units per milliliter.</description>
        <time_frame>One month after booster vaccination (Month 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data were available for antibodies against at least one study vaccine antigen after booster vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="316"/>
                  <measurement group_id="O2" value="101"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Concentration of Antibodies Against Protein D (PD)</title>
            <description>Concentrations of antibodies are presented as geometric mean concentrations expressed as Enzyme-Linked Immuno-Sorbent Assay (ELISA) units per milliliter.</description>
            <units>ELISA units per milliliter</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1288.9" lower_limit="1175.6" upper_limit="1413.2"/>
                  <measurement group_id="O2" value="92.0" lower_limit="78.3" upper_limit="108.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Antibodies Against Polyribosyl-ribitol-phosphate (PRP)</title>
        <description>Concentrations of antibodies are presented as geometric mean concentrations expressed as microgram per milliliter.</description>
        <time_frame>One month after booster vaccination (Month 1)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data were available for antibodies against at least one study vaccine antigen after booster vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Group</title>
            <description>Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="163"/>
                  <measurement group_id="O2" value="54"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Concentration of Antibodies Against Polyribosyl-ribitol-phosphate (PRP)</title>
            <description>Concentrations of antibodies are presented as geometric mean concentrations expressed as microgram per milliliter.</description>
            <units>microgram per milliliter</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="152.970" lower_limit="130.307" upper_limit="179.575"/>
                  <measurement group_id="O2" value="99.738" lower_limit="72.964" upper_limit="136.335"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious AEs were assessed up to one month following booster vaccination (Month 1). The time frames for Other AEs reporting were 4 days and 31 days following booster vaccination for events collected by systematic and non-systematic methods, respectively.</time_frame>
      <desc>Subjects at risk for systematically assessed other (non-serious) adverse events has been set to the number of subjects that had returned their symptom sheet.</desc>
      <group_list>
        <group group_id="E1">
          <title>Synflorix Group</title>
          <description>Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
        </group>
        <group group_id="E2">
          <title>Prevenar Group</title>
          <description>Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain at the injection site</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="332"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Redness at the injection site</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="332"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Swelling at the injection site</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="332"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="332"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="332"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="332"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="332"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
